Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis
NCT00339976 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2017-07-02
Summary
This study is a follow-up to an earlier study that examined the relationship of This study will examine whether exposure to neurotoxins, such as lead, mercury, solvents, and pesticides, can contribute to amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The cause of this degenerative disease of the brain and spinal cord is not well understood. Some studies suggest that exposure to environmental neurotoxins may increase its risk. This follow-up study will examine the relationship of neurotoxin exposure to the interval between the diagnosis of ALS and death. It will also examine the possible roles of genetics, lifestyle and dietary factors in the disease. Information on ALS patients previously enrolled in the study will be used to examine this relationship. No new individuals will be enrolled in the study.
Conditions
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-08-06
- Completion
- 2008-04-21
Countries
- United States
Study Locations
More Related Trials
-
Determining the Safety of L-serine in ALS
NCT01835782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
NCT05349721 ·Status: TERMINATED ·Phase: PHASE2
-
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
NCT03984708 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis
NCT00005766 ·Status: COMPLETED ·Phase: PHASE2
-
Environmental Exposure and Neurological Diseases Questionnaire
NCT02916966 ·Status: COMPLETED
-
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420 ·Status: RECRUITING
-
Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis
NCT04518540 ·Status: UNKNOWN ·Phase: NA
-
ALS Research Collaborative
NCT06885918 ·Status: RECRUITING
-
Mitochondrial Functions and Oxidative Stress in ALS Patients
NCT00331812 ·Status: UNKNOWN
-
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
NCT00561366 ·Status: WITHDRAWN ·Phase: PHASE2
-
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
NCT01091142 ·Status: COMPLETED ·Phase: PHASE1
-
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
NCT05137665 ·Status: RECRUITING
-
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
NCT05053035 ·Status: TERMINATED ·Phase: PHASE2
-
Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05949294 ·Status: WITHDRAWN ·Phase: PHASE1
-
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
NCT00983983 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ALS Reversals 4: LifeTime Exposures
NCT03706391 ·Status: COMPLETED
-
Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)
NCT05107349 ·Status: RECRUITING ·Phase: NA
-
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
ALS Reversals - Lunasin Regimen
NCT02709330 ·Status: COMPLETED ·Phase: PHASE2
-
Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort
NCT00377351 ·Status: COMPLETED
-
Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS)
NCT05880563 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
sCD163 in ALS Patients
NCT02325375 ·Status: COMPLETED
-
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
NCT02424669 ·Status: UNKNOWN ·Phase: NA
-
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
NCT02611674 ·Status: COMPLETED
-
Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis
NCT00069186 ·Status: UNKNOWN ·Phase: PHASE3